PRDM1 and neoplasm: PRDM1, also known as B lymphocyte-induced maturation protein 1 (BLIMP1), has been shown to impair the stemness and growth activity of CAR T cells, as indicated by TCF7, which is closely associated with the exhaustion phenotypes of CAR T cells in anti-tumor therapies (33).